ClinicalTrials.gg
Not yet recruitingNCT07760636CINEFILUpdated Aug 12, 2026

Kinetics and Prognostic Value of NeuroFilament Light in Post-cardiac Arrest: A Prospective Multicenter Study

An observational study in Cardiac Arrest (CA), Intensive Care Unit (ICU) Admission and Return of Spontaneous Circulation, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the prognostic value of absolute value and kinetic of neurofilament light chain (NFL) collected at different time points (at admission, 12h, 24h, 48h, 72h, 96h, and day 7 after ICU admission) in predicting poor and good neurological outcome in comatose patients after cardiac arrest.

Read the detailed description

A large majority of patients resuscitated after cardiac arrest (CA) are comatose following the return of spontaneous circulation and require admission to the intensive care unit (ICU). Unfortunately, many of them die during their ICU stay, mainly following the decision to withdraw life-sustaining therapies due to ischemic and hypoxic brain injuries considered irreversible. Early identification of these neurological injury is therefore one of the major challenges for intensivists, in order to tailor the intensity of care.

Currently, the recommended strategy consists of applying a multimodal prognostic approach. This algorithm allows prediction of poor neurological outcome in approximately 50% of cases, according to various studies. This highlights the need for new early prognostic markers to predict both unfavorable and favorable outcomes.

Regarding biomarkers of brain injury, European guidelines recommend the measurement of serum NSE, a biomarker of neuronal injury that is now commonly used. An NSE level > 60 µg/L at 48 and/or 72 hours after cardiac arrest predicts poor neurological outcome with good accuracy (AUC between 0.80 and 0.92 depending on the study), high specificity but limited sensitivity. Moreover, uncertainty remains regarding the optimal threshold value to use, and variable results have been reported across clinical studies. Finally, early serum NSE levels (within the first 24-48 hours) have limited prognostic value, which restricts their usefulness for the early identification of patients likely to have a poor outcome. These limitations have highlighted the need to identify new biomarkers of brain injury to better assess the prognosis of these patients.

02

Conditions studied

  • Cardiac Arrest (CA)
  • Intensive Care Unit (ICU) Admission
  • Return of Spontaneous Circulation
  • Comatose

Browse trials for

Keywords

  • Cardiac arrest
  • Coma
  • Neuroprognostication
  • Biomarkers
  • Neurofilament light chain
03

In context

Heart Arrest

926 studies on the registry are indexed under Heart Arrest; 226 are open to participants now.

This study's planned enrollment of 270 is above the median of 200 across 376 observational studies indexed under Heart Arrest.

Browse Heart Arrest studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Comatose patients after cardiac arrest

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to the ICU for cardiac arrest,
  • Patients who regained consciousness following in-hospital or out-of-hospital cardiac arrest,
  • Patients in a coma upon arrival in the ICU, defined by a Glasgow Coma Scale (GCS) score \<8,
  • Patients included in the AfterROSC2 cohort,

Exclusion criteria

Exclusion Criteria:

  • Terminally ill patients (death expected within 3 hours of admission to the ICU),
  • Minors,
  • Patients under legal guardianship,
  • Pregnant women,
  • Patients not enrolled in a social security program,
  • Prior inclusion in the CINEFIL study,
  • Restriction of active therapies prior to the first NFL biomarker assay,
  • Objection by a family member or trusted person, if present
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    Patients

    Other: Value of neurofilament light chain (NFL) at different time points

Interventions

  • OtherValue of neurofilament light chain (NFL) at different time points

    Value of neurofilament light chain (NFL) at different time points (H0, H12, H24, H48, H72, H96, and day 7 after ICU admission

06

What researchers measure

Primary outcomes

  1. modified Rankin Scale (mRS)

    Neurological outcome assessed by the modified Rankin Scale (mRS) (An unfavorable outcome is defined as a modified Rankin Scale (mRS) score between 4 and 6 (severe neurological sequelae, persistent coma, or death), and a favorable outcome as a modified Rankin Scale (mRS) score between 0 and 3 (no sequelae, mild to moderate neurological sequelae))

    Time frame: 3 months

Secondary outcomes

  1. Mortality

    Time frame: At ICU discharge, up to 3 months

  2. Early myoclonus

    Clinical, imaging, or neurophysiological neurological abnormalities : early myoclonus (\<72 hours)

    Time frame: <72 hours

  3. Myoclonus status

    Clinical, imaging, or neurophysiological neurological abnormalities: myoclonus status (\<72 hours post-CA)

    Time frame: <72 hours post-CA

  4. Pupillary and corneal reflexes

    Clinical, imaging, or neurophysiological neurological abnormalities: pupillary and corneal reflexes at 72 hours post-CA

    Time frame: 72 hours post-CA

  5. Pupillary and corneal reflexes

    Clinical, imaging, or neurophysiological neurological abnormalities: brain imaging, if performed

    Time frame: 3 months

  6. Electroencephalogram (EEG)

    Neurological abnormalities

    Time frame: 3 months

  7. Somatosensory evoked potentials

    Neurological abnormalities

    Time frame: 3 months

  8. Auditory evoked potentials

    Neurological abnormalities

    Time frame: 3 months

07

Study locations

1 site
  • Medical ICU
    Paris, IDF 75014, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07760636
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Sarah Benghanem, MD PhD
Contact
sarah.benghanem@aphp.fr
+ 00 33 1 58 41 43 3
Marie Benhammani-Godard
Contact
marie.godard@aphp.fr
0033158411190
Sarah Benghanem
principal investigator · Medical ICU, Cochin hospital, Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion